Ambit, Cephalon Pen Kinase Drug-Discovery, Development Alliance | GenomeWeb
NEW YORK (GenomeWeb News) — Ambit Biosciences today said it will combine its KinomeScan-driven discovery technology with Cephalon's chemistry and discovery and development chops to help develop kinase inhibitors.
 
Terms of the deal call for Ambit to screen a “large” library of Cephalon’s kinase-focused compounds to generate “nearly a million data points,” Ambit said. In return, Cephalon will pay Ambit $18 million in an up-front fee to access its KinomeScan technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.